Verona Pharma plc Verona Pharma Plc : Miscellaneous
May 09 2018 - 8:30AM
UK Regulatory
TIDMVRP
LONDON, May 09, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP)
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative therapies
for respiratory diseases, announces that it will present data from its
chronic obstructive pulmonary disease (COPD) clinical trial program with
lead product candidate, RPL554, at the American Thoracic Society
International Conference (ATS) in San Diego, CA from May 18-23, 2018.
RPL554 is a first-in-class, inhaled, dual inhibitor of the enzymes
phosphodiesterase 3 and 4 designed to have anti-inflammatory as well as
bronchodilator properties, and is currently in development for the
maintenance treatment of COPD and for the treatment of cystic fibrosis.
Details of the Company's poster presentations are listed below and the
abstracts are available to the public online at the American Thoracic
Society website (http://conference.thoracic.org/).
Rapid Abstract Poster Discussion Session (Abstract 4227, Poster 9964):
RPL554, A First-In-Class Dual PDE3/4 Inhibitor, Causes Rapid Additional
Bronchodilation When Dosed with Tiotropium in COPD Patients
Session Title: Clinical Trials and Studies in COPD (B102)
Date and Time: Monday, May 21, 2018; 2:15 PM - 4:15 PM PDT
Location: San Diego Convention Center, Room 30 C-E (Upper Level)
Thematic Poster Session (Abstract 3022, Poster 9880): Low Oral
Bioavailability of RPL554, a First-in-Class Dual PDE3/4 Inhibitor,
Demonstrates that Its Nebulized, Inhaled Formulation Is Appropriate for
Delivering Optimal Pulmonary Dose
Session Title: COPD: Maintenance Therapy (B33)
Date and Time: Monday, May 21, 2018; 9:15 AM - 4:15 PM PDT
Location: San Diego Convention Center, Area L (Hall A-B2, Ground Level)
About COPD
Chronic obstructive pulmonary disease (COPD) is a progressive and
life-threatening respiratory disease for which there is no cure.(1) The
condition damages the airways and the lungs, leading to persistent
breathlessness, impacting a person's daily life and their ability to
perform simple activities such as walking a short flight of stairs or
carrying a suitcase.(1) Although COPD is thought to be underdiagnosed,
globally, around 384 million people suffer from the disease.(2) This
number, according to the World Health Organization (WHO), is likely to
increase in coming years, with estimates that COPD will become the third
leading cause of death worldwide by 2030.(1,3) Current COPD therapies
focus on reducing and controlling symptoms. Yet, despite the wide
availability of these treatments, many patients continue to suffer acute
periods of worsening symptoms known as exacerbations. These
exacerbations often lead to emergency department visits or hospital
admissions and are also associated with high mortality.(4) In the
United States alone, the 2010 total annual medical costs related to COPD
were estimated to be $32 billion and are projected to rise to $49
billion in 2020.(5)
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative therapies for the treatment of
respiratory diseases with significant unmet medical needs. Verona
Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual
inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a
bronchodilator and an anti-inflammatory agent in a single compound. In
clinical trials, treatment with RPL554 has been observed to result in
statistically significant improvements in lung function as compared to
placebo, and has shown clinically meaningful and statistically
significant improvements in lung function when administered in addition
to frequently used short- and long-acting bronchodilators as compared to
such bronchodilators administered as a single agent. Verona Pharma is
developing RPL554 for the treatment of chronic obstructive pulmonary
disease (COPD), cystic fibrosis (CF), and potentially asthma.
Forward-Looking Statements
This press release contains forward-looking statements. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including, but not limited to, statements regarding the value of trial
results presented at ATS, RPL554 as a new complementary treatment for
patients with COPD, projected annual medical costs related to COPD, the
future clinical development and positioning of RPL554, and the treatment
potential for RPL554.
These forward-looking statements are based on management's current
expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements
to be materially different from our expectations expressed or implied by
the forward-looking statements, including, but not limited to, the
following: our limited operating history; our need for additional
funding to complete development and commercialization of RPL554, which
may not be available and which may force us to delay, reduce or
eliminate our development or commercialization efforts; the reliance of
our business on the success of RPL554, our only product candidate under
development; economic, political, regulatory and other risks involved
with international operations; the lengthy and expensive process of
clinical drug development, which has an uncertain outcome; serious
adverse, undesirable or unacceptable side effects associated with
RPL554, which could adversely affect our ability to develop or
commercialize RPL554; potential delays in enrolling patients, which
could adversely affect our research and development efforts; we may not
be successful in developing RPL554 for multiple indications; our ability
to obtain approval for and commercialize RPL554 in multiple major
pharmaceutical markets; misconduct or other improper activities by our
employees, consultants, principal investigators, and third-party service
providers; material differences between our "top-line" data and final
data; our reliance on third parties, including clinical investigators,
manufacturers and suppliers, and the risks related to these parties'
ability to successfully develop and commercialize RPL554; and lawsuits
related to patents covering RPL554 and the potential for our patents to
be found invalid or unenforceable. These and other important factors
under the caption "Risk Factors" in our Annual Report on Form 20-F filed
with the Securities and Exchange Commission ("SEC") on February 27, 2018
relating to our Registration Statement on Form F-1, and our other
reports filed with the SEC, could cause actual results to differ
materially from those indicated by the forward-looking statements made
in this press release. Any such forward-looking statements represent
management's estimates as of the date of this press release. While we
may elect to update such forward-looking statements at some point in the
future, we disclaim any obligation to do so, even if subsequent events
cause our views to change. These forward-looking statements should not
be relied upon as representing our views as of any date subsequent to
the date of this press release.
______________________________
(1) World Health Organization. Chronic Obstructive Pulmonary Disease.
http://www.who.int/mediacentre/factsheets/fs315/en/. Accessed September
2017.
(2) Adeloye D, Chua S, et al. Global and regional estimates of COPD
prevalence: Systematic review and meta-analysis. J Glob Health 2015;
5(2): 020415.
(3) World Health Organization. Burden of COPD.
http://www.who.int/respiratory/copd/burden/en/. Accessed September 2017.
(4) COPD Foundations. Characteristics of COPD Patients Using United
States Emergency Care or Hospitalization.
https://journal.copdfoundation.org/jcopdf/id/1103/Characteristics-of-COPD-Patients-Using-United-States-Emergency-Care-or-Hospitalization.
Accessed September 2017.
(5) Center for Disease Control. Increase Expected in Medical Costs for
COPD. https://www.cdc.gov/features/ds-copd-costs/. Accessed September
2017.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44 (0) 20 7710 7600
and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison SNELVeronaPharma@stifel.com
FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727 1000
Simon Conway / Natalie Garland-Collins veronapharma@fticonsulting.
com
ICR, Inc. (US Media and Investor enquiries)
James Heins Tel: +1 203-682-8251
James.Heins@icrinc.com
Stephanie Carrington Tel: +1 646-277-1282
Stephanie.Carrington@icrinc
.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Verona Pharma plc via Globenewswire
http://www.veronapharma.com/
(END) Dow Jones Newswires
May 09, 2018 08:30 ET (12:30 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024